Remove Genetic Analysis Remove Genome Remove RNA Remove Scientist
article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing. Instead of snipping the genome, base editing lets for edits of individual letters in a genetic sequence. Beam employs three approaches to deliver its genetic medicines to cells.

DNA 52
article thumbnail

Unlocking the potential of mRNA for the future treatment of rare diseases 

Drug Discovery World

As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta , PhD, staff scientist in genetic sciences at Thermo Fisher Scientific.